Raman Micro Spectroscopy for In Vitro Drug Screening: Subcellular Localisation and Interactions of Doxorubicin by Farhane, Zeineb et al.
Technological University Dublin 
ARROW@TU Dublin 
Articles DIT Biophotonics and Imaging 
2015-05-01 
Raman Micro Spectroscopy for In Vitro Drug Screening: 
Subcellular Localisation and Interactions of Doxorubicin 
Zeineb Farhane 
Technological University Dublin 
Franck Bonnier 
Technological University Dublin 
Alan Casey 
Technological University Dublin, alan.casey@tudublin.ie 
Hugh Byrne 
Technological University Dublin, hugh.byrne@tudublin.ie 
Follow this and additional works at: https://arrow.tudublin.ie/biophonart 
 Part of the Analytical, Diagnostic and Therapeutic Techniques and Equipment Commons, 
Pharmaceutical Preparations Commons, and the Physics Commons 
Recommended Citation 
“Raman micro spectroscopy for in vitro drug screening: subcellular localisation and interactions of 
Doxorubicin, Z. Farhane, F. Bonnier, A. Casey and H.J. Byrne, Analyst, 140, 4212-4223 (2015) DOI: 
10.1039/c5an00256g 
This Article is brought to you for free and open access by 
the DIT Biophotonics and Imaging at ARROW@TU Dublin. 
It has been accepted for inclusion in Articles by an 
authorized administrator of ARROW@TU Dublin. For more 
information, please contact 
yvonne.desmond@tudublin.ie, arrow.admin@tudublin.ie, 
brian.widdis@tudublin.ie. 
This work is licensed under a Creative Commons 
Attribution-Noncommercial-Share Alike 3.0 License 
Analyst c5an00256g
1
Raman micro spectroscopy for in vitro drug
screening: subcellular localisation and interactions
of doxorubicin
Z. Farhane,* F. Bonnier, A. Casey and H. J. Byrne
Raman spectroscopy is used for the localization and
tracking of chemotherapeutic drug, doxorubicin, in the
intracellular environment of lung cancer cell line. Results
show the potential of the technique to monitor the
mechanisms of action and response on a molecular level,
with subcellular resolution.
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Raman micro spectroscopy for in vitro drug
screening: subcellular localisation and interactions
of doxorubicinQ1
Z. Farhane,*a F. Bonnier,b A. Caseya and H. J. ByrneQ2 a
Vibrational spectroscopy, including Raman spectroscopy, has been widely used over the last few years to
explore potential biomedical applications. Indeed, Raman spectroscopy has been demonstrated to be a
powerful non-invasive tool in cancer diagnosis and monitoring. In confocal microscopic mode, the tech-
nique is also a molecularly specific analytical tool with optical resolution which has potential applications
in subcellular analysis of biochemical processes, and therefore as an in vitro screening tool of the efficacy
and mode of action of, for example, chemotherapeutic agents. In order to demonstrate and explore the
potential in this field, established, model chemotherapeutic agents can be valuable. In study paper,
Raman spectroscopy coupled with confocal microscopy were used for the localization and tracking of
the commercially available drug, doxorubicin (DOX), in the intracellular environment of the lung cancer
cell line, A549. Cytotoxicity assays were employed to establish clinically relevant drug doses for 24 h
exposure, and confocal laser scanning fluorescence microscopy was conducted in parallel with Raman
spectroscopy profiling to confirm the drug internalisation and localisation. Multivariate statistical analysis,
consisting of PCA (principal components analysis) was used to highlight doxorubicin interaction with
cancer cells and spectral variations due to its effects before and after DOX spectral features subtraction
from nuclear and nucleolar spectra, were compared to non-exposed control spectra. Results show that
Raman micro spectroscopy is not only able to detect doxorubicin inside cells and profile its specific sub-
cellular localisation, but, it is also capable of elucidating the local biomolecular changes elicited by the
drug, differentiating the responses in different sub cellular regions. Further analysis clearly demonstrates
the early apoptotic effect in the nuclear regions and the initial responses of cells to this death process,
demonstrating the potential of the technique to monitor the mechanisms of action and response on a
molecular level, with subcellular resolution.
Introduction
Although the potential of vibrational spectroscopy, including
infrared absorption and Raman spectroscopy, for biomedical
applications has been well demonstrated, translation to the
clinical environment has been slow, potentially due to the
demands of standardisation, regulation and extensive clinical
trials.1,2 Fundamentally, the techniques are analytical, with
molecular specificity, and, in the case of Raman spectroscopy
in the confocal microscopy mode, can achieve optical resolu-
tion enabling subcellular profiling in 3D, suggesting that an
appropriate application would be in screening of biomolecular
changes in vitro.3–6 Regulatory requirements in both the EU
and US (EU Directive-2010/63/EU and US Public Law 106-545,
2010, 106th Congress) have increasingly restricted the use of
animal models for development of pharmaceuticals and cos-
metics, and Raman micro spectroscopy offers a potentially low
cost, label free alternative to in vitro High Content Analysis for
routine screening.7,8
The potential of Raman micro spectroscopy in this field has
previously been demonstrated in a number of studies.9,10 The
use of model systems, with established modes of action is of
particular benefit in this respect, and commercially available
drugs such as cisplatin (an alkylating and DNA binding
agent)11,12 and vincristine (an alkaloid agent)13 have been
explored. In these specific studies, however, the drug itself was
not detected, but rather the spectroscopic response profiles of
the cells themselves were correlated with the cytotoxic
responses measured in cells. Nawaz et al., postulated that the
direct chemical interaction of the drug in the cell could be
aFOCAS Research Institute, Dublin Institute of Technology, Kevin Street, Dublin 8,
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bUniversité François-Rabelais de Tours, Faculty of Pharmacy, EA 6295
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differentiated from the resultant cytological response using
multivariate regression, and this approach was recently vali-
dated by Keating et al.14 El-Mashtoly et al.15 utilised the dis-
tinct structure of Erlotinib, containing a carbon–carbon triple
bond, to specifically detect the subcellular presence of the
drug in vitro, while Cuisinier et al. used the CvO stretching
band at 1740 cm−1 to monitor paclitaxel (a microtubule stabi-
lizing agent) in cells and Vigny et al.16 probed the resonance
Raman response to detect and study nonfluorescent tran-
sition-metal complexes, Theraphtal, used as a chemothera-
peutical combination. Raman spectroscopy has also been
demonstrated as a suitable probe of subcellular
localisation17–19 and toxicity of nanoparticles.20–22
One of the 10 most frequent drugs used in cancer chemo-
therapy and especially for the treatment of aggressive and
metastatic tumours is doxorubicin.23 Doxorubicin (DOX) is an
anthracycline antibiotic extract from Streptomyces peucetius
and a well-established anti-cancer drug (since 1960).24 It is
widely used in chemotherapy for a varied range of cancers
including breast carcinoma, haematological malignancies and
lung cancer. Despite its known cardiotoxicity, it is currently
one of the anticancer drugs most used in clinics.25,26 When
taken up into cell nucleus, where it has high affinity for DNA
and blocks topoisomerase II,24,27 DOX induces genotoxicity
and inhibits the process of DNA replication and macromolecu-
lar biosynthesis, leading to tumour cell apoptosis.28 As this
interaction is dependent on the level of protein, cells with
high levels of topoisomerase II are more susceptible to DOX,
which explains its selectivity to cancer cells.24 In addition to
the formation of complex drug-DNA-topoisomerase II, DOX
also induces the formation of DNA adducts,25,29 hydrogen per-
oxide30 and inhibits DNA methyltransferase23 and Transform-
ing Growth Factor-β1 (TGFβ1).31
Despite the wide range of cytotoxicity that DOX elicits, its
complete mechanism of action still not fully understood and
much research has been undertaken to elucidate more clearly
how DOX works, its uptake and intracellular delivery and
resistance of cancer cells.24,32–35 In this context, the technique
of Raman spectroscopy could add additional insight, in vitro.
The anthracycline structure of DOX, consisting of a conjugated
anthraquinone ring structure banded to an aminoglycoside,25
renders it fluorescent and gives it a strong Raman scattering
efficiency even off resonantly, (Fig. 1A). It can therefore poten-
tially be simultaneously tracked inside cells by confocal fluo-
rescence microscopy and Raman spectroscopy, and therefore
is an ideal candidate to probe the sensitivity of the latter to not
only monitor the intracellular interactions of drugs, but also
the mechanisms of interaction and the progression of sub-
sequent cellular responses.
A number of studies over the last few years have investi-
gated either the cellular uptake and nuclear accumulation,36
cytotoxicity or the interaction of free or nanoformulations of
DOX in different cancer cell lines or isolated DNA.34,35,37–40
In this study, Raman micro spectroscopy is used as a tool,
complemented by parallel cytotoxicity assays and confocal
fluorescence microscopy, to both monitor DOX within the
cellular environment, to detect its biochemical effects and
fingerprint the physiological responses in the cancer cell line,
A549, a non-small cell lung adenocarcinoma. The study thus
explores the capability of the technique to screen the uptake
and mechanisms of interaction of chemotherapeutic agents
in vitro in a truly label free manner.
Materials and methods
Cell culture
A549 human lung adenocarcinoma cells with the alveolar type
II phenotype were obtained from ATTC (Manassas, VA, USA).
A549 cells were cultured in DMEM (with 2 mM L-glutamine)
with 10% foetal bovine serum (FBS) at 37 °C in a humidified
atmosphere containing 5% CO2 and cells were split every two
days to maintain ∼60% confluence.
For confocal fluorescence and Raman spectroscopic ana-
lysis, cell number was determined using a Beckman Coulter
Particle Count and Size Analysis® Z2 Cell Counter.
Fig. 1 (A) chemical structure of doxorubicin (B) Raman spectrum of doxorubicin in aqueous solution (785 nm as source, background subtracted,
vector-normalised and baseline corrected).
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Cytotoxicity assays
Alamar blue (AB) and 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl
tetrazolium bromide (MTT) assays were performed in 96 well
plates and a total number of 1 × 105 cells were used to seed
three plates (4 × 103 cells mL−1).
Doxorubicin hydrochloride® powder (Sigma Life Sciences,
Ireland) was diluted in 1 mL sterile water to the required con-
centration. After 24 h incubation, plates were washed with
phosphate buffered saline solution (PBS) and doxorubicin was
added in a range from 0 µM (as a control) to 50 µM.
A solution of 1.5 mL of AB (10× ready to use solution) and
3 mL of MTT stock solution (2.5 mg mL−1, 25 mg MTT/10 mL
PBS) in 30 mL of fresh medium were prepared. AB and MTT
assays were both measured with a Cytotox SpectraMax®M3
plate reader using Soft Max® Pro6.2.2 as software and data was
treated using SigmaPlot 10.0. After 24 h incubation in DOX,
plates were washed with PBS and 100 µL of AB/MTT solution
were added to each well. Plates were then incubated for
3 hours and AB fluorescence was measured before in the plate
reader using 540 nm excitation and 595 nm emission. The
medium was then removed, the plates were washed with PBS
and 100 µL of DMSO (dimethyl sulfoxide) were added in each
well. MTT absorbance was read at 570 nm. All cytotoxicity
assays were made in triplicate and repeated three times.
Confocal laser scanning fluorescence microscopy
Approximately 1 × 104 cells were allowed to attach on uncoated
glass bottom Petri dishes (MatTek Corporation, USA) for
approximately two hours, after which they were covered with
cell culture medium. After 24 h incubation, the medium was
removed and samples were rinsed twice with sterile PBS, new
medium containing DOX corresponding to the IC50 concen-
tration (inhibitory concentration) which is the concentration
that inhibits 50% of cells,41 was added and cells were incu-
bated for 24 h more. At the end, cells were washed twice with
sterile PBS, fixed in formalin (4%, 15 mn) and kept in PBS for
imaging. Control samples without exposure to DOX were also
prepared in parallel, and incubated for 24 h.
Confocal laser scanning fluorescence microscopic images
were recorded using an inverted Zeiss LSM 510 confocal laser
scanning microscope equipped with a ×60 oil immersion
objective. Doxorubicin fluorescence was excited with an argon
ion laser at 488 nm, and the emission was collected at 530 nm.
Raman micro spectroscopy
Cells (∼1 × 104/window) were seeded and incubated on CaF2
windows (Crystan Ltd, UK) for 24 h for both control and
exposure to DOX. Medium was then removed and samples
were rinsed twice with sterile PBS and covered with DOX at the
IC50 concentration. After 24 h incubation, cells were washed
twice with sterile PBS and fixed in formalin (4%, 15 min).
A Horiba Jobin-Yvon LabRAM HR800 spectrometer with a
785 nm, 300 mW diode laser as source, Peltier cooled 16-bit
CCD, 300 lines mm−1 grating and 100 μm confocal hole, was
used for this work. Spectra were acquired in the range from
400 cm−1 to 1800 cm−1 using a ×100 objective (LCPlanN,
Olympus), in dry conditions, for 30 s two times, from three
cell locations: cytoplasm, nucleus and nucleolus, to finally
produce a data set of 30 points per cell location for each
control and exposure to DOX, over a total of 60 cells.
Data analysis
Raman spectral pre-processing and analysis were performed in
Matlab 2013 using algorithms developed in house. Prior to
analysis, spectra were smoothed (Savitsky-Golay filter 5th
order, 7 points), vector normalised, baseline corrected (fifth
order polynomial) and background was subtracted using a
NCLS (non-negatively constrained least squares) algorithm.
Principal components analysis (PCA) was employed as an
unsupervised multivariate approach to analyse data and the
effects of doxorubicin in each cell localisation. The order of
the PCs denotes their importance to the dataset and PC1
describes the highest amount of variation.42,43
Results and discussion
Cytotoxicity assays
Fig. 2 shows the dose dependent cytotoxicity of DOX after 24 h
according to the AB and MTT in vitro cytotoxicity assays. Viabi-
lity is expressed as % compared to control, and the error bars
indicate the standard deviation of six independent replicate
measurements. Both assays indicate a systematic dose depen-
dent response. Neither of the assays indicates a complete loss
of viability of the cell populations over the concentration range
and exposure periods, and this viability cures were fitted
with eqn (1)44
V ¼ Vmin þ ðVmax  VminÞ=ð1þ ðC=IC50ÞnÞ ð1Þ
where V is the % viability, Vmin is the minimum viability, Vmax
is the maximum viability, C is the DOX concentration, n is the
Hill slope, and IC50 is the concentration which elicits 50% of
the maximum response. The IC50 values were determined to
Fig. 2 AB and MTT 24 h dose dependent cytotoxicity of DOX to A549.
Analyst Paper
This journal is © The Royal Society of Chemistry 2015 Analyst, 2015, 00, 1–12 | 3
1
5
10
15
20
25
30
35
40
45
50
55
1
5
10
15
20
25
30
35
40
45
50
55
be 0.42 ± 0.06 μM and 0.55 ± 0.16 μM for AB and MTT, respect-
ively. Although the values overlap within experimental error,
any slight difference in IC50 between AB and MTT may be
because the AB assay is a measure of overall cell metabolism
whereas the MTT assay is the reflection of mitochondrial
activity within the cell. Mitochondria exist within the cells in
all stages of their DNA replication, and are first targeted by
DOX which explains its earlier response and higher
sensitivity.45–47 Since cells will be analysed after 24 h exposure,
the IC50 determined using the MTT assay was used for the rest
of the study.
Confocal laser scanning fluorescence microscopy
Confocal laser scanning fluorescence microscopy was used to
confirm intracellular DOX localization and accumulation.
Fig. 3 illustrates that DOX, after 24 h incubation, is predomi-
nantly accumulated in the cell nuclei, and no trace amounts
are evident in the cytoplasm. The absence of DOX in the cyto-
plasm after 24 h, confirms also that A549 cells do not present
any resistance to the drug.33 It is also notable that fragmenta-
tion of nucleoli within the nucleus is observed upon DOX
treatment for 24 h, confirming that cells are going under
apoptosis.48
Raman micro spectroscopy
The Raman spectrum of DOX powder dissolved in sterile water
at the concentration of 17.25 mM (Fig. 1B) clearly shows peaks
at 1445 and 1570 cm−1, related to skeletal ring vibrations,
specific bands corresponding to C–O, C–O–H and C–H in the
region between 1200 and 1300 cm−1 and ones attributed to
C–C–O and C–O at 440 and 465 cm−1 respectively.49,50 The
same peaks are clearly visible in the spectra of Fig. 4, which
shows the mean spectra of the nucleolar (A), nuclear (B) and
cytoplasmic (C) regions of 30 A549 cells before and after 24 h
exposure to the MTT IC50 concentration of DOX. Grey shading
in the respective spectra indicates regions of interest, which
are discussed further below.
Indeed, a first observation is that, in both the nucleolar and
nuclear spectra, there are discernible peaks at 440, 465, 1085,
1215 and 1245 cm−1 corresponding to DOX (indicated by the
blue shaded regions). These peaks are not evident in the mean
cytoplasmic spectrum, however, consistent with the absence of
any fluorescence in the confocal fluorescence microscopic
images of Fig. 3. Thus, the conjugated structure of DOX
renders it easily visible and therefore traceable intracellularly
using Raman spectroscopy, even without the application of
more complex data mining methods.
Furthermore, it is obvious that many DNA peaks, for
example 669, 728, 782, 830, 1095, 1340 and 1425 cm−1 in the
spectra of nucleus and nucleoli of treated cells (Fig. 4A and B)
are diminished compared to non-treated ones. Note that the
feature at 1425 cm−1 is increased because of the contribution
of the DOX peak at the same wavenumber but after DOX sub-
traction it can be clearly seen that this peak is diminished (see
Fig. 3 In vitro confocal fluorescence images of A549 (A) control and (B) 24 h doxorubicin exposure.
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Fig. 8). These results are in accordance with the expected
changes in cell nuclei, related to the DOX mechanism of
action, by which DNA synthesis is blocked by intercalation
causing changes in DNA conformation (decrease of DNA B
form)13 inducing early cell apoptosis.51,52 (Full details of cellu-
lar peak assignments are given in Table 1). A shift towards
lower wavenumbers is observed for the peak at 1095 cm−1,
corresponding to O–P–O stretching, (shown in the expanded
section of Fig. 4A and B), which may indicate that DOX is also
able to bind to DNA externally, although it is also influenced
by the close proximity of the DOX peak at 1086 cm−1.13 In
addition to effects on DNA related spectral features, small
decreases in protein peaks at 1005, 1320, 1578 and 1665 cm−1
are observed, relative to those of control (further confirmed in
the PCA in Fig. 8). The decrease in intensity of DNA and
protein features is consistent with the onset of apoptosis,
which in turn is consistent with a DOX mechanism of action
by induction of cell apoptosis, consisting of programmed and
intrinsic cell death, DNA fragmentation, membrane blebbing
and consequently interrupted cancer cell growth.48,53,54
In the case of the cytoplasm, a similar spectrum is obtained
before and after exposure to DOX, although subtle changes of
some of the spectral features are apparent (indicated by grey
shaded regions in Fig. 4C), such as a decrease in the 720 cm−1
Fig. 4 Mean spectra of A549 cells (A) nucleolus (green; control, black; exposed) (B) nucleus (red; control, magenta; exposed) (C) cytoplasm (blue;
control, cyan; exposed).
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peak and a discrete increase in that at 1158 cm−1, both corres-
ponding to phosphatidyl choline, one of the major cellular
membrane constituents. A notable decrease is also apparent in
the features at 1303 and 1665 cm−1. These small decreases in
lipid and protein peaks can be explained by the fact that,
although apoptotic cells exhibit major changes in the structure
of DNA, cytoplasmic biochemistry and cell volume, the cellular
membrane and plasma can remain almost intact for more pro-
longed periods. The small increase in the feature at 1158 cm−1
may derive from the initial production of membrane vesicles
synthetized by cells as a way to remove waste and toxins by exo-
cytosis. As this synthesis starts at a later time, no substantial
increase in lipid constituents is observed at this stage.45,54
Although some spectral changes resulting from DOX
exposure are discernible by eye, a more detailed picture is elu-
cidated through multivariate analysis. PCA is therefore
employed to analyse in more detail the effects of DOX exposure
on the spectral profiles of the subcellular regions and, for this,
control and exposed cells were compared and analysed, after
which the raw spectrum of DOX was subtracted using NCLS
and the spectra obtained were compared to those of control.
Figures representing the differentiation of the different spectra
by PCA according to the corresponding PCs were plotted and,
for clarity, the loadings are off set, the dashed horizontal line
in all cases indicating zero loading. As an illustration, Fig. 5
shows (A) PCA of control and (B) exposed and control A549
cells. For control A549 cells, there is a clear differentiation
between the nuclear (including nucleolar) region and the cyto-
plasm by PC1 and, according to the loading, the discriminant
peaks correspond predominantly to DNA and lipids. There is
no discrimination of the nuclear/nucleoli regions according to
PC2, which is an indication of the intrinsic point to point spec-
tral variability.
PCA of both exposed and control cells (Fig. 5B), shows a
separation between control cells (negative) and DOX exposed
cells (positive) according to PC1 and the corresponding
loading is dominated by features of the pure DOX spectrum
(Fig. 6). Notice also that there is a discrimination between the
nuclear region and the cytoplasm for both exposed and non-
exposed cells according to PC2 and the corresponding loading
2 exhibits the same peaks as the loading of PC1 for PCA
control cells only (Fig. 5A), namely those at 1300 and
1440 cm−1 for lipids, 795 and 1095 cm−1 for DNA.
To further elucidate the differences between exposed and
control cells and to better understand the effects of DOX
exposure on the spectral profiles of the different subcellular
regions, PCA was employed for each cell compartment
separately.
Significant discrimination can be seen between the spectra
of each subcellular region of control and exposed cells, whose
origin is represented by the loadings of PC1. In the case of
both the nucleolar and nuclear regions (Fig. 7A and B), the dis-
criminating peaks correspond to DOX (440, 465, 1215 and
1245 cm−1), whereas for the cytoplasm (Fig. 7C) there are no
DOX features evident and the only difference is a decrease in
protein and lipid features (1303, 1450 and 1665 cm−1).
In addition to prominent DOX peaks, in the loadings of
PC1 for the nucleolar and nuclear regions of exposed and
control cells, there are a number of smaller discriminants
peaks which may provide further indications of the mode of
interaction. In order, to better visualise these peaks, the spec-
trum of raw DOX powder in aqueous solution, was subtracted
using NCLS, and the resultant spectra were again subjected to
PCA. (Fig. 8)
As seen in Fig. 8A and B, the loading of PC1 for the nucleo-
lar and nuclear spectra of exposed (DOX subtracted) and
control cells show dominant negative discriminants peaks at
1005, 1320, 1450, 1578 and 1665 cm−1, corresponding to
protein and lipids. As discussed further below, in relation to
Fig. 9, the PC1 of the nucleolar spectra (Fig. 8A) also shows
strong contributions for RNA, at ∼782 and 847 cm−1. Although
they sit on a positive background, negatives bands at 830, 881
and 1095 cm−1 and a positive one at 813 cm−1 are evident in
the PC1 of the nuclear spectra, indicating a conformational
changes (B-form DNA into A-form)13,53 caused by the DOX
intercalation. Changes in features at 1340, 782 and 728 cm−1
are also related to DNA, which again is consistent with
the intercalative mechanism of DOX, inducing a cell
apoptosis. Notably, the DNA feature at 1425 cm−1, obscured in
Fig. 4 by the proximity of the DOX peak also features
prominently.
Table 1 Raman bands observed in spectra of the nucleolus, nucleus
and cytoplasm5,13,53–56
Raman shift
(cm−1) Assignment
669 Thymine and guanine
720 and 1158 C–C–N+ symmetric stretching in
phosphatidylcholine
728 Adenine
765 Tryptophan ring
855 Tyrosine vibration
782 Uracil, cytosine and thymine
784_795 Cytosine and thymine, DNA backbone O–P–O
stretching
813 RNA O–P–O phosphodiester bond, DNA A form
828_830 O–P–O asymmetric stretching, DNA B form
847 Ribose phosphate
881 Deoxyribose ring breathing
936 C–C protein skeleton stretching, α helix
1005 Phenylalanine
1047 RNA P–O stretch, sugar phosphate –C–O–
stretching
1095 DNA PO2
− symmetric stretching
1176 Tyrosine and phenylalanine
1246 Amide III
1252 Adenine
1270 RNA uracil and cytosine ring stretching
1300 RNA cytosine and adenine ring stretching
1303 Lipids C–H vibrations
1340, 1425 and
1578
Adenine and guanine
1320, 1450 CH2 deformation
1578 Proteins
1661 Lipids CvC stretching
1665 Amide I
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In addition, there is a discernible increase of the amide III
peaks at 1245 cm−1 (positive peak in loading 1) which may be
explained by the initial mobilisation of a protein group to the
intercalation site to prevent DNA repair.
To better elucidate any differences in the interaction of
DOX in the nucleus compared to nucleoli, PCA of only nuclear
and nucleolar regions was carried out for cells exposed to DOX
then after DOX subtraction and compared to PCA of control
cells.
Fig. 9A clearly shows differentiation between control
nuclear and nucleolar regions. The loading of PC1
presents positive discriminant peaks corresponding to RNA at
1300, 1270, 1047 and 847 cm−1 and negative ones at 1440 and
830, 1450, 1578 cm−1 attributed to DNA and lipids (Table 1),
consistent with the predominance of DNA in the nuclear
regions with lipids from the membrane and RNA in the
nucleoli.
PCA of exposed nuclear and nucleolar regions (Fig. 9B)
shows a similar differentiation between these two cellular com-
partments, but the loading of PC1 is dominated by spectral
features of DOX. This is consistent with DOX localisation in
both nucleolar and nuclear regions, but more so in the latter,
indicating that DOX is rapidly absorbed in the nuclear region,
intercalated into DNA, and only residual amounts are free to
progress to the nucleoli.
PCA of nucleolar and nuclear regions of control cells
(Fig. 9A) indicates that the differences between these two com-
partments, according to the loading of PC1, correspond to
DNA and RNA. But in the PCA of the same two localisations
after DOX exposure and subtraction (Fig. 9C), additional discri-
minant peaks are evident at 765, 1005, 1320, 1665 cm−1,
corresponding to proteins, although the separation is not so
evident. In addition to DNA depletion, there are also changes
in the profile of nuclear proteins. These features are negative
Fig. 5 (A) PCA of A549 cytoplasm, nucleus and nucleolus control (non-exposed) cells (B) PCA A549 cytoplasm, nucleus and nucleolus for both
exposed and control cells. Cytoplasm , nuclear and nucleolar non-exposed cell. Cytoplasm , nuclear and nucleolar ● exposed cell.
Fig. 6 Loading of PC1 (PCA of control cells vs. exposed) in blue and
doxorubicin spectrum in cyan.
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with respect to PC1, consistent with an increased protein
activity in the nucleoli. The decrease of the feature at
1450 cm−1, corresponding to lipids, may indicate that there is
a denaturation of the cytoplasmic membrane surrounding the
nucleus.
Discussion
In the present study, the chemotherapeutic agent DOX could
clearly be detected and tracked intracellularly within A549
cells using Raman spectroscopy. Results for both Raman
micro spectroscopy and confocal microscopy show that this
anthracycline molecule, after 24 h exposure, is completely
localised inside the cell nucleus, in which DNA is abundant,
consistent with its established mechanism of action by DNA
intercalation.
This nuclear localisation is manifest in the Raman nuclear
and nucleolar spectra by the clear presence of DOX peaks at
465, 445 1200, 1300, 1440 and 1570 cm−1 and the absence of
those peaks in cytoplasm spectra, and in confocal images by
the red fluorescence in nucleus and nucleoli.
More in depth investigations using multivariate analysis
revealed that not only DOX can be detected inside cells, but
also both its biochemical effects and the physiological
responses of the cells to exposure can be seen.
Fig. 7 PCA of exposed and control A549 cells (A) nucleolus (B) nucleus (C) cytoplasm.
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DOX is a known DNA intercalator, and the decrease in the
nuclear spectral features at 669 (thymine and guanine), 728
(adenine), 782 (cytosine and thymine), 1340 and 1425 cm−1
(adenine and guanine) peaks are signatures of intercalation in
the DNA duplex between two neighbouring base pairs, result-
ing in a decrease in the levels of B conformation DNA
(830 cm−1).57,58 Similar results were found for vincristine, a
microtubule binder and mitotic inhibitor, but which was also
observed to intercalate with nuclear DNA in a similar in vitro
exposure of A549 cells, resulting in a diminution of thymine
(669 cm−1), guanine (1317 cm−1), cytosine (782 cm−1) and
adenine (728 cm−1) bands, in addition to a decrease in DNA B
form (827 cm−1).13
A decrease in thymine (669 cm−1) and guanine (1336 cm−1)
bands and to a lesser extent a reduction of the band associated
with DNA conformation (833 cm−1), were also found with cis-
platin, a well-established chemotherapeutic “groove binding”
agent which binds with DNA forming inter-strand and intra-
strand crosslinks at 1,2-GG and 1,3-GTG sites, leading to cell
cycle arrest and apoptosis.11 For these chemotherapeutic
drugs, Raman signatures of the chemical interaction with
nuclear DNA have therefore been established.
Moreover, changes in nuclear proteins are also observed in
the studies related to cisplatin and vincristine, as observed in
the current study of DOX. However, a more notable increase
in some protein peaks, amide III α-helix (1302 cm−1) and
β-sheet (1250–1259 cm−1), CH2 deformation (938 cm−1), inter-
preted as a physiological response of the cell to the chemo-
therapeutic exposure, was apparent for both cisplatin and
vincristine, although it should be stressed that the time
exposure for the cisplatin and vincristine studies was 96 h, as
compared to the 24 h exposure employed in the current study,
making a direct comparison of the responses impossible.
Comparing the spectral changes in exposed nucleoli to
those of nucleus, it is clear that the dominant interaction with
DNA occurs in the nucleus, as expected. However, the spectral
changes in the nucleoli, associated with increased protein
activity may provide additional insight into the early stage cel-
lular response to toxic insult in which the cell nucleoli have
been proposed to play a central role.59
In the case of the cytoplasm, distinct decreases in spectral
features associated with lipids and proteins peaks are observed
after DOX exposure, consistent with an apoptotic cell death
mechanism, along with an increase of phosphatidyl choline, a
marker of a vesicle membrane synthesis as a means to remove
the cytotoxic agent by exocytosis. These results are different
from those obtained for cisplatin, exposure to which results in
a conformational change in cytoplasmic protein, resulting
from the binding of cisplatin, along with a modification in
lipids as a direct chemical effect (disintegration of lipids) and
Fig. 8 A) PCA of exposed nucleolar regions after DOX subtraction (black) versus control cells (green), (B) PCA of exposed nuclear regions after DOX
subtraction (yellow) versus control cells (red).
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physiological response (decrease in lipids due to the reduction
of cell viability).
In summary, distinct Raman spectroscopic markers of
chemotherapeutic agents which interact with nuclear DNA can
be established which can be used to help elucidate the mode
of action of the drug. Changes in nuclear protein features can
give indications of early cellular responses to the toxic insult.
Raman markers for cytoplasmic biochemical effects are also
evident, including decrease in both proteins and lipids, and
subtle differences in the responses to exposure to different
chemical agents can shed further light on the mechanisms of
cellular response.
Conclusion
This study further demonstrates the potential of Raman spec-
troscopy as a truly label free, in vitro screening tool to monitor
the interaction of molecular chemotherapeutic agents on a cel-
lular level. In confocal microscopic mode, the technique offers
Fig. 9 PCA of nucleolar (green) and nuclear (red) regions (A) control (B) after DOX exposure (C) after DOX subtraction.
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the same spatial resolution as confocal laser scanning fluore-
scence microscopy, enabling tracking of the subcellular localis-
ation of the drug.
The conjugated structure of the chosen model drug, doxor-
ubicin, presents a strong Raman scattering cross section,
which renders it spectral profile easily discernible at toxico-
logically relevant doses, even at non resonant wavelengths, above
the intrinsic cellular spectrum. As a model system to explore
the potential of the technique, the conjugated structure also
results in a strong fluorescence such that the measurements
can be supported by conventional, confocal microscopy.
Notably, Raman micro spectroscopy can also elucidate and
differentiate the changes in the biomolecular structure within
the subcellular regions, in this study, the cytoplasm, nucleus
and nucleoli, and potentially shed further light on the mecha-
nisms of interaction of the drug.
Given the drive for a reduction in the use of animal models,
there is currently much promotion of the development of
in vitro models for drug and toxicity screening. Ultimately,
with improved screening sensitivities and speeds, Raman
spectroscopy could be employed to monitor in quasi real time,
in a label free manner, the efficacy and mode of action of,
for example chemotherapeutic agents and other exogeneous
agents, laying the basis for improved quantitative structure–
activity relationships to guide drug development or chemical
regulation strategies.
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